Filing Flows › Pelthos Therapeutics (PTHS) › Q1 2026 › vs Q4 2025
Pelthos Therapeutics (PTHS) Q1 2026 vs Q4 2025 (quarter over quarter)
Pelthos Therapeutics's revenue rose $1.5M (+16%) from $9.4M in Q4 2025 to $10.9M in Q1 2026.
Pelthos Therapeutics, Q1 2026: revenue $10.9M, operating margin -120.0%, net loss $25.1M, operating cash flow −$13.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.9M | $9.4M | $1.5M | +16% |
| Net loss | $25.1M | $21.7M | $3.4M | +16% |
| Costs & expenses | $36.0M | $38.0M | −$2.0M | -5% |
| Operating costs | $24.0M | $21.4M | $2.6M | +12% |
| Interest & other, net | $12.0M | $16.6M | −$4.6M | -28% |
| Cost of revenue | $1.7M | $1.7M | $1K | +0.1% |
| Research & development | $186K | $374K | −$188K | -50% |
| SG&A | $21.1M | $18.5M | $2.6M | +14% |
| Other operating costs | $1.0M | $877K | $154K | +18% |
| Operating cash sources | $25.1M | $21.7M | $3.4M | +16% |
| Depreciation & amortization | $1.5M | $0 | $1.5M | — |
| Share-based compensation | $1.9M | $1.8M | $109K | +6% |
| Working capital & other | $8.5M | $13.6M | −$5.1M | -37% |
| Cash used in operations | $13.1M | $6.3M | $6.9M | +110% |
| Net loss absorbed | $25.1M | $21.7M | $3.4M | +16% |
Questions
How much did Pelthos Therapeutics's revenue grow quarter over quarter in Q1 2026?
Pelthos Therapeutics's revenue rose $1.5M (+16%) from $9.4M in Q4 2025 to $10.9M in Q1 2026.